India · Delayed Price · Currency is INR Advanced Enzyme Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Record revenue and profit growth achieved in FY 2026, with strong performance across all segments and geographies. Margin stability is expected despite inflation and global uncertainties, supported by R&D investments and capacity expansion.
-
Q3 revenue grew 2% year-over-year but declined sequentially, with strong nine-month growth of 15%. Human Healthcare faced headwinds, while Animal Healthcare and Bioprocessing segments delivered robust gains. Management expects double-digit growth ahead, supported by new R&D initiatives.
-
Q2 FY26 saw 26% YoY revenue growth and 42% YoY EBITDA growth, with strong performance across all segments and a 33% EBITDA margin. U.S. tariffs impacted American sales, but management maintains mid-double-digit growth guidance and plans increased R&D investment as a new center comes online.
-
Record quarterly revenue and double-digit growth were driven by strong human and animal healthcare segments, with margins impacted by tariffs and product mix. Management remains optimistic for sustained double-digit growth, supported by ongoing R&D investment and new business initiatives.
Fiscal Year 2025
-
Revenue grew 2% year-over-year to INR 6,369 million in FY25, with stable gross and EBITDA margins. Human nutrition and specialized manufacturing segments showed resilience, while management expects mid-double-digit growth in FY26, supported by innovation and capacity expansion.
-
Q3 FY25 delivered steady growth with revenue up 5% YoY (adjusted for delayed sales), strong EBITDA and PAT margins, and robust performance in animal nutrition, bioprocess, and specialized manufacturing. Management expects single-digit growth for FY25, with innovation and U.S. market expansion as key drivers amid global uncertainties.
-
Q2 saw revenue growth but margin pressure due to deferred sales and higher costs. Full-year growth guidance was revised to single digits, with H2 expected to be stronger as deferred revenue is recognized. U.S. sales remain robust, while R&D investment and new product development continue.
-
Q1 FY25 delivered 5% revenue and 19% PAT growth year-over-year, with strong international sales, especially from the US, offsetting softness in India and Europe. Management maintains 12%-14% full-year growth guidance and expects margin stability, with most growth anticipated in H2.